A weekly injection of semaglutide (2.4 mg) helps lower the risk of serious heart problems like heart attack, stroke, or heart-related death by 20% in people over 45 who have heart disease and are...

In adults over 45 with heart disease and obesity but no diabetes, a weekly injection of semaglutide at 2.4 mg for about 3.3 years lowers the combined risk of heart-related death, heart attack, or stroke compared to a placebo.

For adults with heart disease and obesity who don’t have diabetes, taking a weekly semaglutide shot (2.4 mg) leads to more than twice as many people stopping treatment because of side effects compared to those taking a dummy shot.

In obese adults without diabetes but with heart disease, weekly injections of semaglutide at 2.4 mg led to a higher rate of patients stopping treatment because of side effects compared to those receiving a placebo.

Even if you don’t have diabetes, if you’re overweight and have heart disease, a weekly shot of semaglutide can cut your risk of heart attack or stroke by 1 in 5 — and this benefit starts before you lose much weight.

In obese adults with existing heart disease but no diabetes, a weekly injection of semaglutide at 2.4 mg is associated with a lower rate of serious heart-related events such as heart attack or stroke.